1. A method alisporivira co-administration with one or more drugs, which have the pharmacokinetics and disposition of general in vivo, which is affected by at least one of CYP3A4, P-gp, OATP1B1, OATP1B3, MRP2, BSEP and NTCP, which has alisporivir effect, which achieves and maintains a similar safety and efficacy of these drugs and / or alisporivira at lower doses and less frequent administration, or both, and drugom.2. A method according to Claim. 1, wherein said medicament is an antiviral agent direct action, used in the treatment VGS.3 infection. A method of improving or enhancing the pharmacokinetics of the drug plasma levels, which is metabolized by cytochrome P450-dependent monooxygenase, comprising administering to the patient receiving treatment with the use of smaller doses of the drug, a pharmacokinetic improvement or increase in blood plasma effective amount alisporivira.4. A method according to claim. 2, where alisporivir administered before and / or substantially simultaneously with the drug, where efficacy of the drug is reduced because of its degradation by cytochrome dependent monooksigenazy.5 450. A method of improving or enhancing the pharmacokinetics in plasma drug levels, comprising administering to a patient treated with said drug, a pharmacokinetic improvement or increase in blood plasma alisporivira effective amount, wherein the drug is a substrate of P -glycoprotein and / or cytochrome P450- dependent monooxygenase 3A4.6. A method for improving pharmakos1. Способ совместного введения алиспоривира с одним или несколькими лекарственными средствами, которые имеют фармакокинетику и общую in vivo диспозицию, на которую влияет, по меньшей мере один из CYP3A4, P-gp, OATP1B1, OATP1B3, MRP2, BSEP и NTCP, где алиспоривир обладает эффектом, который достигает и сохраняет сходную безопасность и эффективность указанных лекарственных средств и/или алиспоривира при меньших дозах, менее частом введении или и том, и другом.2. Способ по п. 1, где указанное лекар
